A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

Michelle Gooey, Evelyn Wong, Alisa Pedrana, Nicole Allard, Joseph Doyle, Margaret Hellard, Amanda Wade

Research output: Contribution to journalArticleResearchpeer-review


In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPS) were surveyed twice to assess hepatitis C knowledge and management 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: Baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22 P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (χ2(1) = 5.95, P = 0.02) however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPS is warranted to ensure optimal hepatitis C management in primary care.

Original languageEnglish
Pages (from-to)387–389
Number of pages3
JournalSexual Health
Issue number4
Publication statusPublished - 2020


  • general practice
  • primary care

Cite this